Drug Patents owned by Eagle Pharms

1. Drug name - ARGATROBAN IN SODIUM CHLORIDE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7589106 EAGLE PHARMS Alcohol free formulation of argatroban Sep, 2027

(4 years from now)

US7687516 EAGLE PHARMS Alcohol free formulation of argatroban Sep, 2027

(4 years from now)

Drugs and Companies using ARGATROBAN ingredient

Treatment: Method of treating thrombosis; Method of treating an argatroban treatable condition

Dosage: INJECTABLE;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
50MG/50ML (1MG/ML) INJECTABLE;INTRAVENOUS Discontinued

2. Drug name - BELRAPZO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8791270 EAGLE PHARMS Bendamustine pharmaceutical compositions Jan, 2026

(3 years from now)

US9572796 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US9572797 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US11103483 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US10010533 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US9265831 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US8609707 EAGLE PHARMS Formulations of bendamustine Aug, 2031

(8 years from now)

Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient

Treatment: For the treatment of patients with chronic lymphocytic leukemia; for the treatment of patients with indolent b-cell non-hodgkin lymphoma; For the treatment of patients with indolent b-cell non-hodgkin lymphoma; for the treatment of patients with chronic lymphocytic leukemia

Dosage: SOLUTION;IV (INFUSION)

More Information on Dosage
Strength Dosage Availability
100MG/4ML (25MG/ML) SOLUTION;IV (INFUSION) Prescription

3. Drug name - BENDEKA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8791270 EAGLE PHARMS Bendamustine pharmaceutical compositions Jan, 2026

(3 years from now)

US9265831 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US9572797 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US9572796 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US11103483 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US10010533 EAGLE PHARMS Formulations of bendamustine Jan, 2031

(8 years from now)

US8609707 EAGLE PHARMS Formulations of bendamustine Aug, 2031

(8 years from now)

US9572887 EAGLE PHARMS Formulations of bendamustine Mar, 2033

(10 years from now)

US9579384 EAGLE PHARMS Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration Mar, 2033

(10 years from now)

US9000021 EAGLE PHARMS Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration Mar, 2033

(10 years from now)

US9597398 EAGLE PHARMS Formulations of bendamustine Mar, 2033

(10 years from now)

US9144568 EAGLE PHARMS Formulations of bendamustine Mar, 2033

(10 years from now)

US9597399 EAGLE PHARMS Formulations of bendamustine Mar, 2033

(10 years from now)

US9597397 EAGLE PHARMS Formulations of bendamustine Mar, 2033

(10 years from now)

US9034908 EAGLE PHARMS Formulations of bendamustine Mar, 2033

(10 years from now)

US10052385 EAGLE PHARMS Formulations of bendamustine Mar, 2033

(10 years from now)

Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient

Treatment: For use in treatment of patients with chronic lymphocytic leukemia (cll) and/or non-hodgkin's lymphoma; For the treatment of patients with chronic lymphocytic leukemia; for the treatment of patients with indolent b-cell non-hodgkin lymphoma; For the treatment of patients with indolent b-cell non-hodgkin lymphoma; for the treatment of patients with chronic lymphocytic leukemia; For use in the treatment of patients with chronic lymphocytic leukemia and/or non-hodgkins lymphoma; For the treatment of patients with chronic lymphocytic leukemia

Dosage: SOLUTION;IV (INFUSION)

More Information on Dosage
Strength Dosage Availability
100MG/4ML (25MG/ML) SOLUTION;IV (INFUSION) Prescription

4. Drug name - PEMFEXY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9604990 EAGLE PHARMS Crystalline forms of pemetrexed diacid and manufacturing processes therefor
Oct, 2035

(13 years from now)

Drugs and Companies using PEMETREXED ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
500MG/20ML (25MG/ML) SOLUTION;INTRAVENOUS Prescription

5. Drug name - RYANODEX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8110225 EAGLE PHARMS Treatment using dantrolene Dec, 2022

(2 months from now)

US8604072 EAGLE PHARMS Treatment using dantrolene Dec, 2022

(2 months from now)

US8685460 EAGLE PHARMS Treatment using dantrolene Feb, 2023

(4 months from now)

US7758890 EAGLE PHARMS Treatment using dantrolene Jul, 2025

(2 years from now)

Drugs and Companies using DANTROLENE SODIUM ingredient

Treatment: For use in the treatment of malignant hyperthermia in conjunction with appropriate supportive measures and for the prevention of malignant hyperthermia in patients at high risk.

Dosage: FOR SUSPENSION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
250MG/VIAL FOR SUSPENSION;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.